ClearPoint Neuro, Inc. (CLPT) News
Filter CLPT News Items
CLPT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CLPT News Highlights
- For CLPT, its 30 day story count is now at 2.
- Over the past 27 days, the trend for CLPT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest CLPT News From Around the Web
Below are the latest news stories about CLEARPOINT NEURO INC that investors may wish to consider to help them evaluate CLPT as an investment opportunity.
Those who invested in ClearPoint Neuro (NASDAQ:CLPT) five years ago are up 365%Long term investing can be life changing when you buy and hold the truly great businesses. While the best companies are... |
7 Solid Small-Caps for 2024 and BeyondSmall-cap stocks are positioned to beat the biggest companies in 2024 as risk tolerance climbs and shares remain undervalued |
Are Investors Undervaluing ClearPoint Neuro, Inc. (NASDAQ:CLPT) By 41%?Key Insights The projected fair value for ClearPoint Neuro is US$10.08 based on 2 Stage Free Cash Flow to Equity... |
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q3 2023 Earnings Call TranscriptClearPoint Neuro, Inc. (NASDAQ:CLPT) Q3 2023 Earnings Call Transcript November 9, 2023 ClearPoint Neuro, Inc. beats earnings expectations. Reported EPS is $-0.0002, expectations were $-0.25. Operator: Thank you for standing by, and welcome to the ClearPoint Neuro, Inc. Q3 2023 Earnings Conference Call. Comments made on this call may include statements that are forward-looking within […] |
ClearPoint Neuro Reports Third Quarter 2023 ResultsBiologics & Drug Delivery Growing 55%; Q3 Operational Cash Burn of $1.8MSOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 2023. Third Quarter Highlights Reported quarterly revenue of $5.8 million, a 12% year-over-year increase;Increased biologics and drug delivery revenue |
ClearPoint Neuro to Announce Third Quarter 2023 Results November 9, 2023SOLANA BEACH, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2023 third quarter on Thursday, November 9, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company’s 2023 third quarter on Thursday, November 9, 2023, at 4:30 p.m. Eastern time |
When Should You Buy ClearPoint Neuro, Inc. (NASDAQ:CLPT)?ClearPoint Neuro, Inc. ( NASDAQ:CLPT ), might not be a large cap stock, but it led the NASDAQCM gainers with a... |
ClearPoint Neuro Reports Second Quarter 2023 ResultsBiologics & Drug Delivery growing +40%; Company Reaffirms 2023 Revenue ForecastSOLANA BEACH, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its second quarter ended June 30, 2023. Second Quarter Highlights Reported record quarterly revenue of $6.0 million, a 14% year-over-year increase;Increased biologics and drug deliv |
ClearPoint Neuro to Announce Second Quarter 2023 Results August 8, 2023SOLANA BEACH, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2023 second quarter on Tuesday, August 8, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company’s 2023 second quarter on Tuesday, August 8, 2023, at 4:30 p.m. Eastern time (1:3 |
ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug DeliverySOLANA BEACH, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has entered into a multi-year license agreement with UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical leader, to partner on drug delivery platforms for UCB’s gene therapy portfolio. “We are extremely excited to partner with UCB, a global biopharmaceutical leader, with a focus on inno |